New studies demonstrate the health and cost advantages of iRhythm’s Zio long-term continuous monitoring (LTCM) system.
Advancing Cardiac Care Through Innovation
iRhythm Technologies presented five studies at the 2024 American Heart Association Scientific Sessions, showcasing the Zio monitor’s role in:
- Early arrhythmia detection for chronic conditions like type 2 diabetes and COPD.
- Enhanced patient engagement through digital health tools.
- Insights into arrhythmia patterns during sleep and activity.
“These findings demonstrate Zio’s potential to improve patient outcomes while addressing healthcare costs,” said Dr. Mintu Turakhia, iRhythm’s Chief Medical and Scientific Officer.
Key Study Highlights
1. Improved Compliance via Digital Tools
- Patients using the MyZio app and text notifications achieved a 94.8% compliance rate compared to 74.6% for non-digital users.
- Surveys from over 300,000 patients showed a 14% higher comfort rating for the updated Zio monitor, highlighting the value of patient-centered design.
2. Arrhythmia Insights During Sleep and Activity
- Algorithms using Zio’s accelerometry data matched FDA-cleared actigraphy devices in monitoring sleep and activity patterns.
- Analysis of 24,000 patients revealed arrhythmias like pauses were common during sleep, while ventricular tachycardia was more frequent during activity.
3. Economic Benefits of Early Detection
- Diabetes patients with undetected arrhythmias incurred annual healthcare costs of $34,171 versus $18,687 without arrhythmias.
- COPD patients with arrhythmias faced annual costs of $37,719 compared to $25,656 without.
Transforming Care Through Early Intervention
These studies reinforce Zio’s potential to prevent complications, enhance personalized care, and reduce costs. By detecting arrhythmias early, iRhythm’s technology addresses critical gaps in managing chronic conditions.
Follow MEDWIRE.AI for the latest developments in patient monitoring and healthcare innovation.
